JP2016063817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016063817A5 JP2016063817A5 JP2015217734A JP2015217734A JP2016063817A5 JP 2016063817 A5 JP2016063817 A5 JP 2016063817A5 JP 2015217734 A JP2015217734 A JP 2015217734A JP 2015217734 A JP2015217734 A JP 2015217734A JP 2016063817 A5 JP2016063817 A5 JP 2016063817A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 70
- 239000003814 drug Substances 0.000 claims 59
- 229940127121 immunoconjugate Drugs 0.000 claims 15
- 239000000611 antibody drug conjugate Substances 0.000 claims 12
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- -1 free cysteine amino acid Chemical group 0.000 claims 10
- 125000004452 carbocyclyl group Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 210000004072 lung Anatomy 0.000 claims 5
- 210000001672 ovary Anatomy 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- 210000003932 urinary bladder Anatomy 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 201000011281 bladder sarcoma Diseases 0.000 claims 4
- 229960002173 citrulline Drugs 0.000 claims 4
- 208000011932 ovarian sarcoma Diseases 0.000 claims 4
- 201000008079 ovary sarcoma Diseases 0.000 claims 4
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims 3
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 201000002660 colon sarcoma Diseases 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 201000003866 lung sarcoma Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 201000002025 prostate sarcoma Diseases 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 108010011559 alanylphenylalanine Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001293 nucleolytic effect Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NHKZQYJGWDGXMY-UHFFFAOYSA-N pyridin-2-ylsulfanyl pentanoate Chemical compound CCCCC(=O)OSC1=CC=CC=N1 NHKZQYJGWDGXMY-UHFFFAOYSA-N 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CC(C(*)C(CCC1)N1C(CC(*)C(*)N(*)C(C(*)(*)NC(C(*)N(C)*)=*)=O)=O)C(N(*)*)=O Chemical compound CC(C(*)C(CCC1)N1C(CC(*)C(*)N(*)C(C(*)(*)NC(C(*)N(C)*)=*)=O)=O)C(N(*)*)=O 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92130007P | 2007-03-30 | 2007-03-30 | |
| US60/921,300 | 2007-03-30 | ||
| US93785707P | 2007-06-29 | 2007-06-29 | |
| US60/937,857 | 2007-06-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217609A Division JP5837019B2 (ja) | 2007-03-30 | 2013-10-18 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016063817A JP2016063817A (ja) | 2016-04-28 |
| JP2016063817A5 true JP2016063817A5 (enExample) | 2016-09-08 |
| JP6185540B2 JP6185540B2 (ja) | 2017-08-23 |
Family
ID=42575819
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009534901A Active JP5394246B2 (ja) | 2007-03-30 | 2007-10-26 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| JP2013217609A Active JP5837019B2 (ja) | 2007-03-30 | 2013-10-18 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| JP2015217734A Active JP6185540B2 (ja) | 2007-03-30 | 2015-11-05 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009534901A Active JP5394246B2 (ja) | 2007-03-30 | 2007-10-26 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| JP2013217609A Active JP5837019B2 (ja) | 2007-03-30 | 2013-10-18 | 抗体及びイムノコンジュゲートとこれらの使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP5394246B2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5990947A (ja) * | 1982-11-16 | 1984-05-25 | Matsushita Electronics Corp | 半導体装置 |
| ES2553874T3 (es) * | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| AR083819A1 (es) * | 2010-11-10 | 2013-03-27 | Genentech Inc | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL |
| JP5925875B2 (ja) * | 2011-04-01 | 2016-05-25 | ワイス・エルエルシー | 抗体−薬剤コンジュゲート |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| US20130143237A1 (en) * | 2011-11-29 | 2013-06-06 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
| CA2869704A1 (en) * | 2012-04-04 | 2013-10-10 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (pcadherin) antibody |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| AU2014233385C1 (en) * | 2013-03-15 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| AU2015205753A1 (en) * | 2014-01-10 | 2016-07-21 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating HER2 positive tumors |
| KR20160111469A (ko) * | 2014-01-24 | 2016-09-26 | 제넨테크, 인크. | 항-steap1 항체 및 면역접합체를 사용하는 방법 |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| MY198629A (en) | 2014-07-24 | 2023-09-11 | Genentech Inc | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
| EP3356409A2 (en) * | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| US11530274B2 (en) * | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
| TWI894130B (zh) | 2018-12-03 | 2025-08-21 | 美商艾澤西公司 | 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法 |
| KR20220130749A (ko) * | 2020-01-22 | 2022-09-27 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| CN111494645B (zh) * | 2020-05-20 | 2022-09-30 | 中国药科大学 | 抗人dll4人源化抗体与美登素生物碱dm1的偶联物及其制备方法与应用 |
| WO2022247708A1 (en) * | 2021-05-24 | 2022-12-01 | Remegen Co., Ltd. | Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer |
| KR20230015301A (ko) | 2021-07-19 | 2023-01-31 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1244705B1 (en) * | 1999-12-06 | 2010-01-27 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
| CA2563735C (en) * | 2004-04-22 | 2020-07-14 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
| KR101270829B1 (ko) * | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
-
2007
- 2007-10-26 JP JP2009534901A patent/JP5394246B2/ja active Active
-
2013
- 2013-10-18 JP JP2013217609A patent/JP5837019B2/ja active Active
-
2015
- 2015-11-05 JP JP2015217734A patent/JP6185540B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016063817A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| JP2010523469A5 (enExample) | ||
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| JP2012522512A5 (enExample) | ||
| JP2014139173A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| JP2013056896A5 (enExample) | ||
| JP2015523380A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2017110002A5 (enExample) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| WO2018204872A3 (en) | Igf-1r monoclonal antibodies and uses thereof | |
| RU2011140491A (ru) | Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 | |
| JP2011507932A5 (enExample) | ||
| JP2016098233A5 (enExample) | ||
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| JP2012519711A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| RU2016143119A (ru) | Конъюгаты анти-ртк7 антитело-лекарственное средство | |
| JP2015534577A5 (enExample) | ||
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты |